Carboplatin vinorelbine

INDICATION: Non-small cell lung cancer Stage III/IV

Prior to a course of chemotherapy

- Baseline bloods: FBC, U&E, LFT, Ca
- Creatinine clearance (Cockcroft-Gault formula)
- CT thorax
- Histological/cytological confirmation
- If appropriate discuss need for contraception and risk of infertility (offer sperm banking for males)
- Written informed consent for course

Prior to each cycle

- FBC, U&E, LFT, Ca
- FBC, U&Es (day 8)
- CXR
- Creatinine clearance (calculated) if Serum creatinine increases by > 20% different consider dose adjustment
- Medical review

Vinorelbine§	25mg/m ²	Over 5 min in 50ml N/Saline	Day 1 and 8
Carboplatin*	AUC 5	Over 1 hour in 500 ml Dextrose 5%	Day 1

Repeat every 21 days for up to 6 cycles

(Vinorelbine 60mg/m² oral may be given on days 1 and 8 instead of IV. Ondansetron 8mg bd should be given with day 8 oral vinorelbine)

§ Maintain extravasation precautions throughout administration as Vinorelbine is a moderate vesicant

Give a sodium chloride 0.9% flush afterwards to minimise vein pain

*AUC 5 calculated as (Creatinine Clearance + 25) x 5

Dose modification for haematological toxicity				
<u>DAY 1</u>	Neutrophils > 1.5 AND Platelets>100	Proceed with full dose		
•	Neutrophils 1.0-1.5	Discuss with consultant		
•	Neutrophils < 1.0 OR Platelets < 100	Defer 1 week		
<u>DAY 8</u>				
•	Neutrophils > 1.0 AND Platelets >100	Proceed with full dose		
•	Neutrophils < 1.0 OR Platelets <100	Defer until recovery		
If there has been a dose delay reduce subsequent treatment doses by 20%				
Dose modification for neurological toxicity				
•	Grade 3+	Consider change from Vinorelbine to less neurotoxic agent		

Expected toxicities	
Neutropenic sepsis & thrombocytopenia	Nausea & vomiting (severe)
Constipation	Peripheral neuropathy
Alopecia (mild)	Mucositis
Arm/Jaw pain	

This protocol has been reviewed by the Lancashire & South Cumbria Lung Oncology Consultants' Group and responsibility for the template lies with the Head of Service.

Date: September 2019

Next review: September 2021